Business
Dario Unveils Groundbreaking GLP-1 and AI-Personalization Digital Health Findings
DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced four new studies presented this past weekend at the 85th Annual American Diabetes Association ("ADA") Scientific Sessions in Chicago. The research, which represents Dario's 25th published study at the ADA's Scientific Sessions over the last decade, includes groundbreaking findings in sustaining GLP-1 weight loss and artificial intelligence ("AI")-powered personalization that
About this update from Dariohealth Corp.
[{"type":"text","content":"Dario's new research shows sustained outcomes post-GLP-1 for platform users and 89% accuracy in innovative AI blood glucose prediction; the Company is actively working to leverage these findings in commercial discussions","length":224,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, June 24, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced four new studies presented this past weekend at the 85th Annual American Diabetes Association ("ADA") Scientific Sessions in Chicago. The research, which represents Dario's 25th published study at the ADA's Scientific Sessions over the last decade, includes groundbreaking findings in sustaining GLP-1 weight loss and artificial intelligence ("AI")-powered personalization that highlight the Company's platform's critical contribution in the digital health market.","length":683,"tagName":"p"},{"type":"image","alt":"DarioHealth_Logo","displaySize":"","headline":null,"caption":"DarioHealth_Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":351,"url":"https://media.zenfs.com/en/prnewswire.com/aeba40a2dbbcfe9e74c653d4eb6528da"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ARomhhCf.qvSHdwl6r9xhw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTYxOTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/aeba40a2dbbcfe9e74c653d4eb6528da","width":400,"height":351}}},{"type":"text","content":"Key highlights from the research include a dramatic eA1c reduction from 9.0% to 6.7% in GLP-1 users, with users seeing sustained results for six (6) months after medication discontinuation, and AI predictive accuracy of 89% for future glucose levels, demonstrating Dario's unique position to deliver value in the GLP-1 market where payers and employers seek solutions that maximize their investment in these costly medications.The Company is currently leveraging these findings in ongoing implementations and commercial discussions with payers and self-insured employers seeking integrated solutions for chronic condition management, particularly around GLP-1 optimization programs.","length":690,"tagName":"p"},{"type":"text","content":"Landmark GLP-1 Study Demonstrates Sustainable Results Beyond Medication","length":71,"tagNa...